자궁경부암 백신 시장 규모는 2024년에는 50억 8,000만 달러로 평가되었고 2026-2032년에 걸쳐 13.94%의 연평균 복합 성장률(CAGR)을 나타내, 2032년에는 144억 8,000만 달러에 달할 것으로 예측됩니다.
여성에서 자궁경부암 증가율은 특히 우려되는 곳이지만, 이것은 자궁경부암이 상당히 일반적인 암이며, 사망 원인의 제1위일 가능성이 있기 때문입니다. 촉진요인은 세계 유병률의 상승입니다. 자궁경부암 환자 수의 세계 급증, 특히 개발 도상국에서의 급증은 저비용으로 새로운 백신을 개발하려는 주요 기업의 의욕을 불러 일으키고 있습니다. 자궁경부암의 이환율 증가는 정부와 비영리 단체가 자궁경부암의 제어와 예방, HPV 예방 접종에 대한 의식을 높이기위한 이니셔티브를 취하는 것을 자극하고 있습니다. 세계 시장 보고서는 시장의 전반적인 평가를 설명합니다. 주요 부문, 동향, 시장 성장 촉진요인, 억제요인, 경쟁 구도, 시장에서 중요한 역할을 하는 요인 등을 종합적으로 분석합니다.
세계의 자궁경부암 백신 시장 정의
자궁경부암은 여성의 자궁경부(질에서 자궁 입구)에 발생하는 암의 일종입니다. 자궁경부암의 약 99%는 고위험형 인유두종 바이러스(HPV)의 감염이 원인입니다.
자궁경부암의 치료에는 수술, 방사선치료, 화학요법 등이 있습니다. 그리고 자궁경부암 예방 접종은 여성의 자궁경부암을 일으키는 HPV 감염의 예방에 중요한 역할을 합니다.
이 백신은 소녀와 여성이 바이러스에 감염되기 전에 접종하면 자궁경부암의 대부분의 경우를 예방할 수 있습니다. 친은 성적 접촉을 갖고 HPV에 노출되기 전 9세부터 접종할 수 있습니다.
세계의 자궁경부암 백신 시장 개요
자궁경부암 환자는 세계적으로 증가하고 있으며, 자궁경부암 백신 수요가 높아질 가능성이 있습니다. 또한, 약 4,290명의 여성이 자궁경부암으로 사망한다고 보여지고 있어 이것은 역사적으로 미국 여성의 암 사망의 주 요원 중 하나였습니다. 자궁경부암 백신은 HPV 감염에 대한 특정 항체를 일생 지속시키는 것입니다.
조사 연구에서는 어떤 HPV 백신에도 사망 예는 없지만 몇 가지 부작용이 있습니다. 두통, 발열, 메스꺼움, 현기증을 일으킬 수 있다고 합니다. 또한, 신흥국이나 저개발국에 있어서의 국가 예방 접종 프로그램의 확립은 세계의 자궁경부암 백신 시장을 확대할 가능성이 있습니다.
Cervical Cancer Vaccine Market size was valued at USD 5.08 Billion in 2024, and the market size will reach USD 14.48 Billion by 2032, growing at a CAGR of 13.94% from 2026 to 2032.
The rising rate of cervical cancer among women is of particular concern because it may be a significantly common form of cancer and the number one reason for death. Its increasing prevalence worldwide is a major driver for the Cervical Cancer Vaccine Market. The worldwide surge in the number of cervical cancer patients, especially in developing countries, has motivated key players to develop new vaccines at a low cost. Furthermore, the growing incidence of cervical cancer has provoked governments and non-profit organizations to take the initiative to raise awareness regarding the control & prevention of cervical cancer and HPV vaccinations. The Global Cervical Cancer Vaccine Market report provides a holistic evaluation of the market. The report offers a comprehensive analysis of key segments, trends, drivers, restraints, competitive landscape, and factors that are playing a substantial role in the market.
Global Cervical Cancer Vaccine Market Definition
Cervical cancer is a type of cancer that occurs in the cervix of the female body, at the opening of the womb from the vagina. The early symptoms of cervical cancer include unusual vaginal bleeding, such as bleeding after sex or between periods. Almost all cases of cervical cancer are caused by a very common virus called human papillomavirus. Around 99% of all cervical cancer caused due to infection with high-risk human papillomaviruses (HPV). HPV develops an abnormal growth of the tissue at the cervix if the infection stays inside the cervix for a long time. Thus, certain abnormal growth of the tissues such as warts can lead to cancer in the cervix.
Treatments for cervical cancer include surgery, radiotherapy, and chemotherapy. According to the World Health Organization, Cervical cancer is the fourth most common type of cancer in women around the world. However preventive measures can reduce the risk of increasing positive cases around the world. Cervical cancer vaccination plays a vital role in the prevention of the HPV infection that causes cervical cancer in women. The HPV vaccine helps to protect the body against infection with human papillomavirus or HPV that results in causing cancers.
The vaccine can prevent most cases of cervical cancer if given before a girl or woman is exposed to the virus. The World Health Organization has recommended the HPV vaccine for girls ages 11 or 12 through national immunization programs. However, the vaccine can be given as early as age 9 before they have sexual contact and are exposed to HPV. According to the Centers for Disease Control and Prevention (CDC), it is recommended that patients receive two doses of HPV vaccine at intervals of six months. Nowadays, taking a three-dose schedule as previously directed is unnecessary.
Global Cervical Cancer Vaccine Market Overview
Cervical cancer cases are increasing globally, which may increase the demand for cervical vaccines. According to the American Cancer Society, 14,480 new cases of invasive cervical cancer will be diagnosed in the United States in 2021. Furthermore, around 4,290 women will die from cervical cancer, which was historically one of the leading causes of cancer death in American women. The Cervical Cancer Vaccine ensures the persistence of particular antibodies against HPV infection for the rest of one's life. The effectiveness and acceptability of the Cervical Cancer Vaccine would be considerably enhanced if the protection was long-lasting and did not require regular boosters throughout life. As a result, the efficiency of the vaccine is critical.
Although investigations and research have found no deaths associated with any HPV vaccine, there are some side effects. These are minor, but they have the potential to become a major market constraint. According to the American Cancer Society, the HPV vaccine might cause headaches, fevers, nausea, and dizziness. Furthermore, the establishment of a national immunization program in developing and underdeveloped nations can expand the global Cervical Cancer Vaccine Market.
The Global Cervical Cancer Vaccine Market is segmented Based on Product Type, Distribution Channel, And Geography.
Based on Product Type, the market is bifurcated into Gardasil, Gardasil 9, and Cervarix. Gardasil accounted for the largest market share in 2020 and is projected to grow at a CAGR of 14.42% during the forecast period. Gardasil is a human papillomavirus (HPV) vaccine. It is a suspension for injection that contains purified proteins for four types of human papillomavirus (types 6, 11, 16, and 18). It is available in vials or prefilled syringes. Gardasil is used in males and females from the age of nine years to protect against the following conditions caused by specific types of human papillomavirus (HPV) such as precancerous lesions (growths) in the cervix, vulva or vagina and anus; cervical and anal cancers; genital warts.
Based on the Application, the market has been segmented into Hospitals, Government Entities, and Clinics. Hospitals accounted for the largest market share in 2020 and are projected to grow at the highest CAGR of 14.65% during the forecast period. Government Entities was the second-largest market in 2020, and it is projected to grow at the highest CAGR.
Based on Geography, the market is classified into Asia Pacific, Middle East & Africa, and Latin America. The Asia Pacific accounted for the largest market share and the Middle East & Africa was the second-largest market in 2020. Asia's economy continues to grow steadily, with strong progress in trading. The region is one of the leading and fastest-growing economies in the global market. The Asia Pacific region is likely to witness the highest growth in the global cervical cancer vaccine market over the forecast period owing to the extension of the already strong biologics market in the region, and the availability of screening tests and vaccine development potential as well.
The "Global Cervical Cancer Vaccine Market" study report will provide valuable insight with an emphasis on the global market. The major players in the market are Merck & Co. Inc., GlaxoSmithKline plc., Sanofi, AstraZeneca PLC, Bristol, and Others.